Page last updated: 2024-10-28

lidocaine and Brain Diseases

lidocaine has been researched along with Brain Diseases in 17 studies

Lidocaine: A local anesthetic and cardiac depressant used as an antiarrhythmia agent. Its actions are more intense and its effects more prolonged than those of PROCAINE but its duration of action is shorter than that of BUPIVACAINE or PRILOCAINE.
lidocaine : The monocarboxylic acid amide resulting from the formal condensation of N,N-diethylglycine with 2,6-dimethylaniline.

Brain Diseases: Pathologic conditions affecting the BRAIN, which is composed of the intracranial components of the CENTRAL NERVOUS SYSTEM. This includes (but is not limited to) the CEREBRAL CORTEX; intracranial white matter; BASAL GANGLIA; THALAMUS; HYPOTHALAMUS; BRAIN STEM; and CEREBELLUM.

Research Excerpts

ExcerptRelevanceReference
"Four hundred two patients with suspected myocardial infarction seen within 6 hours of the onset of symptoms entered a double-blind randomized trial of lidocaine vs placebo."9.05Prophylactic lidocaine in the early phase of suspected myocardial infarction. ( Adgey, AA; Campbell, NP; Dunn, HM; Kinney, CD; MacKenzie, G; McComb, JM; Shanks, RG, 1985)
"Some previous reports indicate that the excitability of the brain may be increased for days following enflurane anesthesia."7.66Lidocaine and pentylenetetrazol seizure thresholds in cats are not reduced after enflurane anesthesia. ( Amory, DW; Heavner, JE, 1981)
" The pathophysiology of POCD remains elusive, but previous work showed that intravenous lidocaine may be protective against POCD, possibly by modulating cerebral inflammation."5.22Effect of intravenous lidocaine on the transcerebral inflammatory response during cardiac surgery: a randomized-controlled trial. ( Berger, M; Cooter, M; Klinger, RY; Levy, JH; Mathew, JP; Newman, MF; Ortel, TL; Podgoreanu, MV; Rinder, HM; Stafford-Smith, M; Welsby, IJ, 2016)
"These data show that cerebral protection by lidocaine, which is unrelated to any effect on depression or anxiety, and is at a level that is noticed by the patients."5.09Cerebral protection by lidocaine during cardiac operations. ( Gorman, DF; Mitchell, SJ; Pellett, O, 1999)
"Four hundred two patients with suspected myocardial infarction seen within 6 hours of the onset of symptoms entered a double-blind randomized trial of lidocaine vs placebo."5.05Prophylactic lidocaine in the early phase of suspected myocardial infarction. ( Adgey, AA; Campbell, NP; Dunn, HM; Kinney, CD; MacKenzie, G; McComb, JM; Shanks, RG, 1985)
"To determine the diagnostic use of intravesical lidocaine, we evaluated its effects on the overactive bladder in patients with brain lesions, spinal lesions, benign prostatic hyperplasia (BPH) and idiopathic overactive bladder."3.70Diagnostic value of intravesical lidocaine for overactive bladder. ( Kodama, K; Komatsu, K; Namiki, M; Niikura, S; Yokoyama, O; Yotsuyanagi, S, 2000)
"Some previous reports indicate that the excitability of the brain may be increased for days following enflurane anesthesia."3.66Lidocaine and pentylenetetrazol seizure thresholds in cats are not reduced after enflurane anesthesia. ( Amory, DW; Heavner, JE, 1981)
"Lidocaine was not neuroprotective."2.74Cerebral protection by lidocaine during cardiac operations: a follow-up study. ( Davies, E; Frampton, C; Gorman, DF; Grieve, D; Merry, AF; Mills, BP; Milsom, FP; Mitchell, SJ; Webster, CS; Willcox, TW, 2009)
"Pretreatment with cimetidine resulted in a significant, dose-dependent decrease in the CD50 of lidocaine, whereas ranitidine pretreatment did not significantly alter the lidocaine CD50."1.27Effects of cimetidine and ranitidine on local anesthetic central nervous system toxicity in mice. ( Kim, KC; Tasch, MD, 1986)

Research

Studies (17)

TimeframeStudies, this research(%)All Research%
pre-19907 (41.18)18.7374
1990's5 (29.41)18.2507
2000's3 (17.65)29.6817
2010's2 (11.76)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Klinger, RY1
Cooter, M1
Berger, M1
Podgoreanu, MV1
Stafford-Smith, M1
Ortel, TL1
Welsby, IJ1
Levy, JH1
Rinder, HM1
Newman, MF1
Mathew, JP1
Duenas, SM1
Pun, J1
Radwan, HA1
Akerman, M1
Schulder, M1
Mitchell, SJ2
Merry, AF1
Frampton, C1
Davies, E1
Grieve, D1
Mills, BP1
Webster, CS1
Milsom, FP1
Willcox, TW1
Gorman, DF2
Gorman, D1
Huang, YL1
Williams, C1
HIGASHINO, KI1
Heavner, JE1
Amory, DW1
Sadato, A1
Taki, W1
Nakahara, I1
Nishi, S1
Yamashita, K1
Matsumoto, K1
Tanaka, M1
Kikuchi, H1
Avery, JK1
Pellett, O1
Yokoyama, O1
Komatsu, K1
Kodama, K1
Yotsuyanagi, S1
Niikura, S1
Namiki, M1
Raskin, NH1
Fishman, RA1
Yan, H1
Jiang, C1
Oldfield, EH1
Friedman, R1
Kinsella, T1
Moquin, R1
Olson, JJ1
Orr, K1
DeLuca, AM1
Kim, KC1
Tasch, MD1
Dunn, HM1
McComb, JM1
Kinney, CD1
Campbell, NP1
Shanks, RG1
MacKenzie, G1
Adgey, AA1
Vincent, FM1
Vincent, T1
Runge, M1
Augustin, HJ1
Dörner, V1

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Lidocaine For Neuroprotection During Cardiac Surgery[NCT00938964]550 participants (Actual)Interventional2009-07-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Change in Center for Epidemiological Studies Depression Scale (CES-D)

"Center for Epidemiological Studies Depression Scale (CES-D). The CES-D is a 20-item self-report examination designed to measure symptoms of depression. Subjects rate the degree to which they have experienced a range of symptoms of depression, such as I had crying spells and I felt lonely. Scores range from 0 to 60, with higher scores indicating greater depressive symptoms. Scores greater than 16 are typically considered indicative of clinically significant depression." (NCT00938964)
Timeframe: baseline, 1-year

Interventionunits on a scale (Mean)
Lidocaine-1.27
Placebo-0.89

Change in Center for Epidemiological Studies Depression Scale (CES-D)

"Center for Epidemiological Studies Depression Scale (CES-D). The CES-D is a 20-item self-report examination designed to measure symptoms of depression. Subjects rate the degree to which they have experienced a range of symptoms of depression, such as I had crying spells and I felt lonely. Scores range from 0 to 60, with higher scores indicating greater depressive symptoms. Scores greater than 16 are typically considered indicative of clinically significant depression." (NCT00938964)
Timeframe: baseline, 6-weeks

Interventionunits on a scale (Mean)
Lidocaine0.57
Placebo0.16

Change in Cognitive Function From Baseline

To characterize cognitive function over time, while minimizing potential redundancy in the cognitive measures, a factor analysis was performed on the 14 cognitive test scores from baseline. We chose a five-factor solution, which represents 5 cognitive domains: structured verbal memory, unstructured verbal memory, executive function, visual memory and attention/concentration. To quantify overall cognitive function, a baseline cognitive index was first calculated as the mean of the 5 preoperative domain scores. The cognitive index score has a mean of zero, thus any positive score is above the mean, any negative score is below the mean. A continuous change score was then calculated by subtracting the baseline from the 1 year cognitive index. The resulting outcome measure is unbounded with standard deviation of 0.35. A negative change score indicating decline and a positive score indicating improvement (NCT00938964)
Timeframe: 1 year after surgery

Interventionunits on a scale (Mean)
Lidocaine0.09
Placebo0.07

Change in Cognitive Function From Baseline Characterized as Continuous Cognitive Change

To characterize cognitive function over time, while minimizing potential redundancy in the cognitive measures, a factor analysis was performed on the 14 cognitive test scores from baseline. We chose a five-factor solution, which represents 5 cognitive domains: structured verbal memory, unstructured verbal memory, executive function, visual memory and attention/concentration. To quantify overall cognitive function, a baseline cognitive index was first calculated as the mean of the 5 preoperative domain scores. The cognitive index score has a mean of zero, thus any positive score is above the mean, any negative score is below the mean. A continuous change score was then calculated by subtracting the baseline from the 6-week cognitive index. The resulting outcome measure is unbounded with standard deviation of 0.35. A negative change score indicating decline and a positive score indicating improvement. (NCT00938964)
Timeframe: Preoperative to 6 weeks after surgery

Interventionunits on a scale (Mean)
Lidocaine0.07
Placebo0.07

Change in Duke Activity Status Index (DASI)

"The DASI is a 12-item scale of functional capacity that has been found to correlate well with objective measures of maximal exercise capacity. Items reflect activities of personal care, ambulation, household tasks, sexual function, and recreational activities. Activities done with no difficulty receive scores, which are weighted and summed, for a quantitative measure of functional status. Scores range from 0 to 60; a higher-weighted score indicates better function." (NCT00938964)
Timeframe: baseline, 1-year

Interventionunits on a scale (Mean)
Lidocaine6.3
Placebo6.96

Change in Duke Activity Status Index (DASI)

"The DASI is a 12-item scale of functional capacity that has been found to correlate well with objective measures of maximal exercise capacity. Items reflect activities of personal care, ambulation, household tasks, sexual function, and recreational activities. Activities done with no difficulty receive scores, which are weighted and summed, for a quantitative measure of functional status. Scores range from 0 to 60; a higher-weighted score indicates better function." (NCT00938964)
Timeframe: baseline, 6-weeks

Interventionunits on a scale (Mean)
Lidocaine-10.98
Placebo-11.67

Change in Neurological Function, as Measured by the National Institutes of Health Stroke Scale (NIHSS)

The National Institutes of Health Stroke Scale (NIHSS) is a 15-item neurologic examination stroke scale used to evaluate the effect of acute cerebral infarction on the levels of consciousness, language, neglect, visual-field loss, extraocular movement, motor strength, ataxia, dysarthria, and sensory loss. A trained observer rates the patent's ability to answer questions and perform activities. Ratings for each item are scored with 3 to 5 grades with 0 as normal, and there is an allowance for untestable items. The range of scores is from 0 (normal) to 42 (profound effect of stroke on patient). (NCT00938964)
Timeframe: baseline, 1-year

Interventionunits on a scale (Mean)
Lidocaine0.05
Placebo0.07

Change in Neurological Function, as Measured by the National Institutes of Health Stroke Scale (NIHSS)

The National Institutes of Health Stroke Scale (NIHSS) is a 15-item neurologic examination stroke scale used to evaluate the effect of acute cerebral infarction on the levels of consciousness, language, neglect, visual-field loss, extraocular movement, motor strength, ataxia, dysarthria, and sensory loss. A trained observer rates the patent's ability to answer questions and perform activities. Ratings for each item are scored with 3 to 5 grades with 0 as normal, and there is an allowance for untestable items. The range of scores is from 0 (normal) to 42 (profound effect of stroke on patient). (NCT00938964)
Timeframe: baseline, 6-weeks

Interventionunits on a scale (Mean)
Lidocaine0.05
Placebo0.04

Change in Neurological Function, as Measured by the Western Perioperative Neurologic Scale (WPNS)

The Western perioperative neurologic scale was designed to detect neurologic deficits after cardiac surgery. It includes 14 items classified into eight domains (mentation, speech, cranial nerve function, motor weakness, sensation and cerebellum, reflexes, and gait). Each item is scored from 0 (severe deficit) to3 (normal), and a maximum score of 42 indicates normal neurological function. (NCT00938964)
Timeframe: baseline, 1-year

Interventionunits on a scale (Mean)
Lidocaine0.02
Placebo-0.02

Change in Neurological Function, as Measured by the Western Perioperative Neurologic Scale (WPNS)

The Western perioperative neurologic scale was designed to detect neurologic deficits after cardiac surgery. It includes 14 items classified into eight domains (mentation, speech, cranial nerve function, motor weakness, sensation and cerebellum, reflexes, and gait). Each item is scored from 0 (severe deficit) to3 (normal), and a maximum score of 42 indicates normal neurological function. (NCT00938964)
Timeframe: baseline, 6-weeks

Interventionunits on a scale (Mean)
Lidocaine0.04
Placebo-0.01

Change in Perceived Social Support

"Perceived Social Support Scale: Twelve items indicate how strongly subjects agree that there is a special person who is around when I am in need and my family really tries to help me. Choices range from very strongly disagree to very strongly agree. Items are summed for a range of 12 to 84, with a high score meaning more social support." (NCT00938964)
Timeframe: baseline, 1-year

Interventionunits on a scale (Mean)
Lidocaine0.71
Placebo-1.16

Change in Perceived Social Support

"Perceived Social Support Scale: Twelve items indicate how strongly subjects agree that there is a special person who is around when I am in need and my family really tries to help me. Choices range from very strongly disagree to very strongly agree. Items are summed for a range of 12 to 84, with a high score meaning more social support." (NCT00938964)
Timeframe: baseline, 6-weeks

Interventionunits on a scale (Mean)
Lidocaine1.23
Placebo-0.49

Change in Social Activity

"Social Activity: This measure consisted of eight items that indicate the degree of social interaction. Sample items are How often do you talk on the telephone with friends and relatives? and How often do you attend meetings of social groups, clubs, or civic organizations? Scores range from 8 to 32. A lower score indicates more social activity." (NCT00938964)
Timeframe: baseline, 1-year

Interventionunits on a scale (Mean)
Lidocaine-0.20
Placebo0.03

Change in Social Activity

"Social Activity: This measure consisted of eight items that indicate the degree of social interaction. Sample items are How often do you talk on the telephone with friends and relatives? and How often do you attend meetings of social groups, clubs, or civic organizations? Scores range from 8 to 32. A lower score indicates more social activity." (NCT00938964)
Timeframe: baseline, 6-weeks

Interventionunits on a scale (Mean)
Lidocaine0.95
Placebo1.59

Change in Spielberger State Anxiety Inventory (STAI)

"Spielberger State Anxiety Inventory (STAI): The STAI consists of two 20-item scales that measure anxiety. Representative items include statements such as I feel nervous and I feel worried. These items are rated on a 4-point scale, based on how well they describe the patient's current or typical mood, from not at all to very much so. Scores range from 20 to 80, with higher scores indicating greater anxiety." (NCT00938964)
Timeframe: baseline, 1-year

Interventionunits on a scale (Mean)
Lidocaine-6.70
Placebo-6.39

Change in Spielberger State Anxiety Inventory (STAI)

"Spielberger State Anxiety Inventory (STAI): The STAI consists of two 20-item scales that measure anxiety. Representative items include statements such as I feel nervous and I feel worried. These items are rated on a 4-point scale, based on how well they describe the patient's current or typical mood, from not at all to very much so. Scores range from 20 to 80, with higher scores indicating greater anxiety." (NCT00938964)
Timeframe: baseline, 6-weeks

Interventionunits on a scale (Mean)
Lidocaine-7.12
Placebo-6.31

Change in Symptom Limitations

Symptom limitations: Patients were given a list of eight symptoms and asked to rate the degree to which the symptom limited daily activities. The symptoms were angina, shortness of breath, arthritis, back trouble, leg pains, headaches, fatigue, and other. Scores range from 8 to 32, with higher scores indicating greater limitations. (NCT00938964)
Timeframe: baseline, 1-year

Interventionunits on a scale (Mean)
Lidocaine-1.39
Placebo-1.48

Change in Symptom Limitations

Symptom limitations: Patients were given a list of eight symptoms and asked to rate the degree to which the symptom limited daily activities. The symptoms were angina, shortness of breath, arthritis, back trouble, leg pains, headaches, fatigue, and other. Scores range from 8 to 32, with higher scores indicating greater limitations. (NCT00938964)
Timeframe: baseline, 6-weeks

Interventionunits on a scale (Mean)
Lidocaine-0.67
Placebo-0.8

Change in the Cognitive Difficulties Scale

"Cognitive Difficulties Scale: a 39-item scale, is a self-report assessment of perceived problems in long- and short-term memory, concentration, attention, and psycho-motor coordination. Sample items are I forget errands I planned to do and I fail to recognize people I know. Scores range from 39 to 164, with higher scores indicating greater cognitive difficulty." (NCT00938964)
Timeframe: baseline, 1-year

Interventionunits on a scale (Mean)
Lidocaine-0.46
Placebo-1.02

Change in the Cognitive Difficulties Scale

"Cognitive Difficulties Scale: a 39-item scale, is a self-report assessment of perceived problems in long- and short-term memory, concentration, attention, and psycho-motor coordination. Sample items are I forget errands I planned to do and I fail to recognize people I know. Scores range from 39 to 164, with higher scores indicating greater cognitive difficulty." (NCT00938964)
Timeframe: baseline, 6-weeks

Interventionunits on a scale (Mean)
Lidocaine-3
Placebo-3.21

Change in the Duke Older Americans Resources and Services Procedures- Instrumental Activities of Daily Living (OARS-IADL)

"Duke Older Americans Resources and Services Procedures- Instrumental Activities of Daily Living (OARS-IADL): This measure contains six items that assess the ability to perform important tasks for daily living (e.g., Could you prepare your own meals? Could you drive a car?). Scores range from 6 to 24. Higher scores indicate increasing difficulty in engaging in daily activities." (NCT00938964)
Timeframe: baseline, 1-year

Interventionunits on a scale (Mean)
Lidocaine-0.15
Placebo-0.31

Change in the Duke Older Americans Resources and Services Procedures- Instrumental Activities of Daily Living (OARS-IADL)

"Duke Older Americans Resources and Services Procedures- Instrumental Activities of Daily Living (OARS-IADL): This measure contains six items that assess the ability to perform important tasks for daily living (e.g., Could you prepare your own meals? Could you drive a car?). Scores range from 6 to 24. Higher scores indicate increasing difficulty in engaging in daily activities." (NCT00938964)
Timeframe: baseline, 6-weeks

Interventionunits on a scale (Mean)
Lidocaine2.46
Placebo2.1

Count of Participants With a Decline of Greater Than or Equal to One Standard Deviation in One or More of Five Cognitive Domain Scores Reported as a Dichotomous Post-operative Cognitive Deficit (POCD) Outcome

To characterize cognitive function over time, while minimizing potential redundancy in the cognitive measures, a factor analysis was performed on the 14 cognitive test scores from baseline. We chose a five-factor solution, which represents 5 cognitive domains: structured verbal memory, unstructured verbal memory, executive function, visual memory and attention/concentration. Each domain score is normally distributed with a mean of zero. A change score was calculated for each domain by subtracting the baseline from the 6-week score. A dichotomous outcome variable of post-operative cognitive deficit was defined as a decline of ≥1 standard deviation in 1 or more of the 5 domains. (NCT00938964)
Timeframe: Preoperative to 6 weeks after surgery

InterventionParticipants (Count of Participants)
Lidocaine87
Placebo83

Change in Study 36-Item Short Form Health Survey (SF-36)

The Medical Outcomes Study 36-Item Short Form Health Survey (SF-36): The SF-36 was designed to measure general health status. Two scales were used: Work Activities (four items) and General Health (one item). For the work activities scale, the reported score was the sum of four questions, each with values ranging from 1 to 4, the total score could range from 4 to 16. A higher score on Work Activities indicates more health-related problems For the general health question, the patients ranked their health from Excellent (1) to poor (5), the scale ranged from 1 to 5 with 1 being best health and 5 being worst. A high score in General Health indicates poorer health state. (NCT00938964)
Timeframe: baseline, 1-year

,
Interventionunits on a scale (Mean)
1 year Change Work Activities1 year Change General health perception
Lidocaine-1.37-0.28
Placebo-1.42-0.43

Change in Study 36-Item Short Form Health Survey (SF-36)

The Medical Outcomes Study 36-Item Short Form Health Survey (SF-36): The SF-36 was designed to measure general health status. Two scales were used: Work Activities (four items) and General Health (one item). For the work activities scale, the reported score was the sum of four questions, each with values ranging from 1 to 4, the total score could range from 4 to 16. A higher score on Work Activities indicates more health-related problems For the general health question, the patients ranked their health from Excellent (1) to poor (5), the scale ranged from 1 to 5 with 1 being best health and 5 being worst. A high score in General Health indicates poorer health state. (NCT00938964)
Timeframe: baseline, 6-weeks

,
Interventionunits on a scale (Mean)
6-Week Change Work activities6-Week Change General health perception
Lidocaine2.71-0.004
Placebo3-0.03

Transcerebral Activation Gradient of Platelet-neutrophil Conjugates

Paired jugular venous and radial arterial blood samples were drawn at baseline, cross-clamp removal, end of cardiopulmonary bypass, and 6 hours post cross-clamp removalime points and analyzed by fluorescence-activated cell sorting to identify activated platelets. Transcerebral activation gradients were calculated by subtracting arterial values from venous values and were compared between groups (NCT00938964)
Timeframe: Baseline to 6 hours post cross-clamp removal

,
InterventionMean linear fluorescence intensity-MLFI (Mean)
BaselineCross-clamp removalEnd of Bypass6 hours post cross-clamp removal
Lidocaine-0.150.02-0.73-0.10
Placebo-0.43-0.73-0.400.19

Transcerebral Activation Gradients of Monocytes

Paired jugular venous and radial arterial blood samples were drawn at baseline, cross-clamp removal, end of cardiopulmonary bypass, and 6 hours post cross-clamp removalime points and analyzed by fluorescence-activated cell sorting to identify activated platelets. Transcerebral activation gradients were calculated by subtracting arterial values from venous values and were compared between groups (NCT00938964)
Timeframe: Baseline to 6 hours post cross-clamp removal

,
InterventionMean linear fluorescence intensity-MLFI (Mean)
BaselineCross-clamp removalEnd of Bypass6 hours post cross-clamp removal
Lidocaine-4.22-2.46-0.341.21
Placebo-0.041.832.640.54

Transcerebral Activation Gradients of Neutrophils

Paired jugular venous and radial arterial blood samples were drawn at baseline, cross-clamp removal, end of cardiopulmonary bypass, and 6 hours post cross-clamp removal and analyzed by fluorescence-activated cell sorting to identify activated platelets. Transcerebral activation gradients were calculated by subtracting arterial values from venous values and were compared between groups (NCT00938964)
Timeframe: Baseline to 6 hours post cross-clamp removal

,
InterventionMean linear fluorescence intensity-MLFI (Mean)
BaselineCross-clamp removalEnd of Bypass6 hours post cross-clamp removal
Lidocaine-2.020.560.581.04
Placebo-0.080.171.19-0.68

Transcerebral Activation Gradients of Platelets

Paired jugular venous and radial arterial blood samples were drawn at baseline, cross-clamp removal, end of cardiopulmonary bypass, and 6 hours post cross-clamp removalime points and analyzed by fluorescence-activated cell sorting to identify activated platelets. Transcerebral activation gradients were calculated by subtracting arterial values from venous values and were compared between groups (NCT00938964)
Timeframe: Baseline to 6 hours post cross-clamp removal

,
InterventionMean linear fluorescence intensity-MLFI (Mean)
BaselineCross-clamp removalEnd of Bypass6 hours post cross-clamp removal
Lidocaine-0.030.030.330.37
Placebo0.350.430.050.27

Reviews

1 review available for lidocaine and Brain Diseases

ArticleYear
Neurologic disorders in renal failure (first of two parts).
    The New England journal of medicine, 1976, Jan-15, Volume: 294, Issue:3

    Topics: Blood-Brain Barrier; Brain Diseases; Cerebrospinal Fluid Proteins; Diazepam; Epilepsy; Humans; Lidoc

1976

Trials

6 trials available for lidocaine and Brain Diseases

ArticleYear
Effect of intravenous lidocaine on the transcerebral inflammatory response during cardiac surgery: a randomized-controlled trial.
    Canadian journal of anaesthesia = Journal canadien d'anesthesie, 2016, Volume: 63, Issue:11

    Topics: Adult; Aged; Anesthetics, Local; Brain Diseases; Cardiac Surgical Procedures; Cardiopulmonary Bypass

2016
A Randomized Trial on the Efficacy of Topical Anesthesia for Pain Reduction during Frame Placement for Gamma Knife Radiosurgery.
    Stereotactic and functional neurosurgery, 2016, Volume: 94, Issue:4

    Topics: Administration, Topical; Adult; Aged; Anesthetics, Local; Brain Diseases; Forehead; Humans; Lidocain

2016
Cerebral protection by lidocaine during cardiac operations: a follow-up study.
    The Annals of thoracic surgery, 2009, Volume: 87, Issue:3

    Topics: Brain Diseases; Cardiac Surgical Procedures; Cognition Disorders; Double-Blind Method; Female; Follo

2009
Cerebral protection by lidocaine during cardiac operations.
    The Annals of thoracic surgery, 1999, Volume: 67, Issue:4

    Topics: Adult; Aged; Anti-Arrhythmia Agents; Anxiety; Brain Diseases; Depression; Double-Blind Method; Femal

1999
[Application of acupuncture anesthesia during craniocerebral operation in temporo-fronto-occipital region].
    Zhen ci yan jiu = Acupuncture research, 1990, Volume: 15, Issue:2

    Topics: Acupuncture Analgesia; Adjuvants, Anesthesia; Adolescent; Adult; Aged; Brain Abscess; Brain Diseases

1990
Prophylactic lidocaine in the early phase of suspected myocardial infarction.
    American heart journal, 1985, Volume: 110, Issue:2

    Topics: Adult; Aged; Arrhythmias, Cardiac; Brain Diseases; Cardiovascular Diseases; Clinical Trials as Topic

1985

Other Studies

10 other studies available for lidocaine and Brain Diseases

ArticleYear
A lignocaine infusion worsens the leukoencephalopathy due to a carbon monoxide exposure in sheep.
    Toxicology, 2003, Apr-15, Volume: 186, Issue:1-2

    Topics: Animals; Brain Diseases; Carbon Monoxide Poisoning; Female; Immunohistochemistry; Lidocaine; Neuropr

2003
An invalidated state followed the shock due to xylocaine-anesthesia.
    The science reports of the research institutes, Tohoku University. Ser. C, Medicine. Tohoku Daigaku, 1959, Volume: 9

    Topics: Analgesia; Anesthesia; Anesthesia and Analgesia; Brain; Brain Diseases; Lidocaine; Pain; Pain Manage

1959
Lidocaine and pentylenetetrazol seizure thresholds in cats are not reduced after enflurane anesthesia.
    Anesthesiology, 1981, Volume: 54, Issue:5

    Topics: Anesthesia; Animals; Brain Diseases; Cats; Enflurane; Female; Lidocaine; Male; Pentylenetetrazole; S

1981
Improved provocative test for the embolization of arteriovenous malformations--technical note.
    Neurologia medico-chirurgica, 1994, Volume: 34, Issue:3

    Topics: Amobarbital; Arteriovenous Malformations; Brain Diseases; Cerebral Angiography; Cerebral Arteries; E

1994
Routine procedure--bad outcome.
    Tennessee medicine : journal of the Tennessee Medical Association, 1998, Volume: 91, Issue:7

    Topics: Aged; Anesthetics, Local; Bradycardia; Brain Diseases; Bronchoscopy; Drug Overdose; Heart Arrest; Hu

1998
Diagnostic value of intravesical lidocaine for overactive bladder.
    The Journal of urology, 2000, Volume: 164, Issue:2

    Topics: Administration, Intravesical; Adolescent; Adult; Aged; Aged, 80 and over; Brain Diseases; Humans; Li

2000
Reduction in radiation-induced brain injury by use of pentobarbital or lidocaine protection.
    Journal of neurosurgery, 1990, Volume: 72, Issue:5

    Topics: Animals; Brain; Brain Diseases; Dose-Response Relationship, Radiation; Lidocaine; Monitoring, Physio

1990
Effects of cimetidine and ranitidine on local anesthetic central nervous system toxicity in mice.
    Anesthesia and analgesia, 1986, Volume: 65, Issue:8

    Topics: Anesthetics, Local; Animals; Brain Diseases; Cimetidine; Dose-Response Relationship, Drug; Drug Inte

1986
Tocainide encephalopathy.
    Neurology, 1985, Volume: 35, Issue:12

    Topics: Aged; Brain Diseases; Humans; Lidocaine; Male; Tocainide

1985
[Cerebral symptoms in xylocaine intoxication].
    Archiv fur Toxikologie, 1971, Volume: 28, Issue:1

    Topics: Apnea; Blood Pressure; Brain; Brain Diseases; Humans; Lidocaine; Male; Middle Aged; Muscle Cramp

1971